Herantis Pharma granted almost €3 million government loan for Parkinson’s study

News

Author: Parkinson's Life editorsPublished: 15 August 2015

Parkinson's LifePrep: Parkinson's LifeCook: Parkinson's LifeServes:

News image

Tekes, the Finnish Funding Agency for Innovation, has granted a €2,903,000 loan to Herantis Pharma Plc to support its clinical study of CDNF for the treatment of Parkinson’s disease. The loan was granted conditionally, subject to obtaining regulatory approval for the clinical study.

Pekka Simula, CEO of Herantis Pharma, added: “We are very excited about our opportunity to translate the results of years of leading academic research to clinical stage, hopefully for the benefit of as many patients as possible.”

Herantis aims to start its clinical development programme with regulatory submissions in Finland and Sweden by the end of 2015. Patient treatments are expected to begin in the first half of 2016. The company expects to recruit 18 patients with Parkinson’s disease in this first-in-human study of CDNF.

Go Back

Share this story

Comments


Related articles


Women and Parkinson's

“It’s so important to be clear about how people can help you”

Ingrid Roesner on speaking up with Parkinson’s disease

READ MORE
Chris Mamo

Interviews

Chris Mamo: 40,000 steps in 12 hours for Parkinson’s

The fundraiser who didn’t stop running for 12 hours

READ MORE
Illustration of crowd of people

Global update

World Brain Day 2020: “join our bandwagon to end Parkinson’s”

From the high cost of medication to a delay in Parkinson’s treatment due

READ MORE